The occasional review by Dr Garrett et al (March 1995;50:303-1 ) concerning asthma mortality and morbidity in New Zealand illustrates the considerable confusion that can arise from selective use of time trend data when it is shaped to fit a preconceived hypothesis that is unsupported by other evidence.
Leaving aside the fenoterol or ,B agonist issues, the time trend data simply do not support a socioeconomic "cause" for the New Zealand epidemic. First, the epidemic commenced in 1976 whereas unemployment only began to increase significantly in 1978.' Secondly, while unemployment was 50 000 in 1980 at the peak of the epidemic, it subsequently rose to well over 200 000 during the time that asthma mortality fell to the lowest levels for 30 years. Thirdly, during the period of the second New Zealand epidemic there were no epidemics of deaths from other causes, many of which are more strongly related to unemployment and social deprivation. Lastly, when New Zealand experienced the first epidemic of asthma mortality in the mid 1960s there was no unemployment. Thus, although social deprivation and poor access to health care clearly plays a part in some asthma deaths, the time trend data are strongly inconsistent with the hypothesis that there was a socioeconomic cause for the epidemic.
While the authors do not mention these anomalies, they do suggest 11 They had a similar non-attendance rate (38%) to us, despite which they were able to show a significantly lower readmission rate (OR 2 3) analysed on an intention to treat basis for those randomised to the clinic. Mayo et al 12 found a threefold reduction in readmission rate over three years in a group of patients randomised to intensive treatment compared with usual treatment within the outpatient setting, and this difference was largely due to the fourfold increase in use of inhaled corticosteroids in the intensive treatment group. This would explain why readmission rates began to drop in New Zealand in 1987 within two years of high dose inhaled steroids being registered for use by specialists only and two years before the debate on inhaled fenoterol began.
Whilst no study has yet shown benefit from changing from regular inhaled bronchodilator therapy to that of as required use only, there are many studies which show substantial benefit from the introduction of higher dose inhaled steroids. The major escalation in inhaled steroid sales in New Zealand therefore remains the most logical explanation for the reduction in both morbidity and mortality, particularly in view of the continued increase in sales of inhaled f agonists. We have no doubt that each ofthe initiatives discussed was necessary and important and contributed to the decline in mortality rates for some considerable time before 1989. However, in their evaluation of trends they do not account for the fact that first ( fig  5) and total (fig 7) hospital admission rates remained obstinately unchanged until 1989, despite the fact that all of the measures outlined in their review were implemented on a nationwide basis well before that time.
The only new strategy adopted in 1989 was the withdrawal of fenoterol followed by recommendations to use P agonists as required rather than as regular treatment. This practice is now accepted in international guidelines for the management of asthma. The first of these steps was prompted by epidemiological data from Wellington,' and the second by the results of a study conducted in Dunedin which showed that control of asthma deteriorated when fenoterol was given regularly rather than as required to patients with mild to moderate asthma. 2 The results of these investigations were complementary. They indicated not only an increased risk of death from asthma among patients receiving inhaled fenoterol, but also that the underlying cause was likely to be an increase in baseline severity when inhaled fenoterol was being taken regularly. We have recently discussed the relationship between ,B agonist use and asthma morbidity and mortality in greater detail. 3 It is therefore quite understandable that improvements in the delivery of and access to medical care -by whatever mechanismsreduced asthma mortality before 1989, but the available data indicate that they had little impact on improving severity and hence morbidity, particularly first hospital admissions. Only when the major factor affecting severity was removed was there a subsequent reduction in morbidity. DR AUTHORS' REPLY Drs Taylor and Wong are correct in stating that it is our contention that the dramatic decline in asthma morbidity and mortality in New Zealand was due to multiple factors and that the precise contribution of individual factors cannot be accurately estimated retrospectively. However, on the one hand they agree that the possible contribution of the withdrawal of fenoterol was acknowledged, but immediately make the accusation that we "exclude(d) the withdrawal of fenoterol as one of them". In a retrospective cohort study we have also shown that fenoterol was associated with an increased risk of fatal or near-fatal asthma (crude RR = 2-1).' However, because of more accurate, complete and detailed information on asthma severity we were better able to control for confounding by severity. After controlling for multiple risk factors, fenoterol was no longer associated with an increased
